IntraBio’s platform technology results from decades of research and over $350 million of investments from organizations worldwide. Our pipeline has broad applicability to be developed as novel treatments for rare (“orphan”) and common neurological disorders, as well as ageing/extending healthspan.

Our lead compound (IB1001) is characterized by a well-established safety and tolerability profile and has a unique potential to address the underlying neurological symptoms and manifestations across a spectrum of genetic and common disorders.

IB1001 is initially being developed for multiple orphan indications where there are currently no FDA approved therapies: Niemann-Pick Disease Type C (NPC), GM1 & GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), and inherited Cerebellar Ataxias (CA).

In addition to its lead compound series, IB1000, IntraBio has developed a robust pipeline of compounds.
IB2000s: The IB2000 (Diferuloylmethane analogues) series has demonstrated clinical efficacy and safety in observational studies for Ménière’s disease.

IB3000s: The IB3000 series (NAADP analogues and agonists) have demonstrated in pre-clinical studies enormous potential to elucidate new molecular pathways, thereby creating opportunities to treat a wide range of diseases from Type 2 Diabetes to autism, to neurodegenerative disorders.

IB4000: IB4000 (UDCA) has been used in observational clinical studies for the treatment of NPC liver dysfunction, showing clinical efficacy and safety. IB4000 has been granted Orphan Drug Designation in both the US and EU for the treatment of NPC.

IB5000: IB500 (Betahistine combination therapy) has demonstrated clinical efficacy and safety in observational studies  for Ménière’s disease.

Privacy Policy Cookies Policy ©2024 IntraBio. All rights reserved.